Potentially Modifiable Factors Associated with Adherence to Adjuvant Endocrine Therapy among Breast Cancer Survivors: A Systematic Review

被引:46
作者
Toivonen, Kirsti I. [1 ]
Williamson, Tamara M. [1 ]
Carlson, Linda E. [2 ,3 ]
Walker, Lauren M. [2 ,3 ]
Campbell, Tavis S. [1 ]
机构
[1] Univ Calgary, Dept Psychol, Calgary, AB T2N 1N4, Canada
[2] Univ Calgary, Dept Oncol, Calgary, AB T2N 1N4, Canada
[3] Tom Baker Canc Clin, Dept Psychosocial Resources, Holy Cross Site, Calgary, AB T2S 3C1, Canada
基金
加拿大健康研究院;
关键词
review; adherence; breast cancer; adjuvant endocrine therapy; ORAL HORMONAL-THERAPY; QUALITY-OF-LIFE; MEDICATION ADHERENCE; SELF-EFFICACY; AROMATASE INHIBITORS; POSTMENOPAUSAL WOMEN; PSYCHOSOCIAL FACTORS; EARLY DISCONTINUATION; TAMOXIFEN THERAPY; CLINICAL-PRACTICE;
D O I
10.3390/cancers13010107
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adjuvant endocrine therapy (AET) reduces risk of breast cancer recurrence. However, suboptimal adherence and persistence to AET remain important clinical issues. Understanding factors associated with adherence may help inform efforts to improve use of AET as prescribed. The present systematic review examined potentially modifiable factors associated with adherence to AET in accordance with PRISMA guidelines (PROSPERO registration ID: CRD42019124200). All studies were included, whether factors were significantly associated with adherence or results were null. This review also accounted for the frequency with which a potentially modifiable factor was examined and whether univariate or multivariate models were used. This review also examined whether methodological or sample characteristics were associated with the likelihood of a factor being associated with AET adherence. A total of 68 articles were included. Potentially modifiable factors were grouped into six categories: side effects, attitudes toward AET, psychological factors, healthcare provider-related factors, sociocultural factors, and general/quality of life factors. Side effects were less likely to be associated with adherence in studies with retrospective or cross-sectional than prospective designs. Self-efficacy (psychological factor) and positive decisional balance (attitude toward AET) were the only potentially modifiable factors examined >= 10 times and associated with adherence or persistence >= 75% of the time in both univariate and multivariate models. Self-efficacy and decisional balance (i.e., weight of pros vs. cons) were the potentially modifiable factors most consistently associated with adherence, and hence may be worth focusing on as targets for interventions to improve AET adherence among breast cancer survivors.
引用
收藏
页码:1 / 22
页数:22
相关论文
共 50 条
[41]   Influence of Patient and Treatment Factors on Adherence to Adjuvant Endocrine Therapy in Breast Cancer [J].
Bender, Catherine M. ;
Gentry, Amanda L. ;
Brufsky, Adam M. ;
Casillo, Frances E. ;
Cohen, Susan M. ;
Dailey, Meredith M. ;
Donovan, Heidi S. ;
Dunbar-Jacob, Jacqueline ;
Jankowitz, Rachel C. ;
Rosenzweig, Margaret Q. ;
Sherwood, Paula R. ;
Sereika, Susan M. .
ONCOLOGY NURSING FORUM, 2014, 41 (03) :274-285
[42]   Identifying adherence barriers to oral endocrine therapy among breast cancer survivors [J].
Rutugandha Paranjpe ;
Grace John ;
Meghana Trivedi ;
Susan Abughosh .
Breast Cancer Research and Treatment, 2019, 174 :297-305
[43]   Strategies to self-manage side-effects of adjuvant endocrine therapy among breast cancer survivors: an umbrella review of empirical evidence and clinical guidelines [J].
Hall, Louise H. ;
King, Natalie V. ;
Graham, Christopher D. ;
Green, Sophie M. C. ;
Barber, Alice ;
Neal, Richard D. ;
Foy, Robbie ;
Clark, Jane ;
Lloyd, Kelly E. ;
Smith, Samuel G. .
JOURNAL OF CANCER SURVIVORSHIP, 2022, 16 (06) :1296-1338
[44]   Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer [J].
Meneveau, Max O. ;
Keim-Malpass, Jessica ;
Camacho, T. Fabian ;
Anderson, Roger T. ;
Showalter, Shayna L. .
BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (03) :805-816
[45]   The relationship among psychosocial adaptation, medication adherence and quality of life in breast cancer women with adjuvant endocrine therapy [J].
Jiang, Haoran ;
Dong, Yu ;
Zong, Wei ;
Zhang, Xiu-jie ;
Xu, Hui ;
Jin, Feng .
BMC WOMENS HEALTH, 2022, 22 (01)
[46]   Duration of adjuvant endocrine therapy of breast cancer: how much is enough? [J].
Ward, John H. .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2010, 22 (01) :51-55
[47]   Compliance and persistence of endocrine adjuvant breast cancer therapy [J].
Gueth, Uwe ;
Myrick, Mary Elizabeth ;
Kilic, Nerbil ;
Eppenberger-Castori, Serenella ;
Schmid, Seraina Margaretha .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) :491-499
[48]   Managing Symptom Distress: Key Factors for Patients on Adjuvant Endocrine Therapy for Breast Cancer [J].
Post, Kathryn E. ;
Ahmad, Zeba ;
Jankauskaite, Greta ;
Centracchio, Joely ;
Oswald, Laura ;
Horick, Nora ;
Park, Elyse R. ;
Temel, Jennifer S. ;
Greer, Joseph A. ;
Jacobs, Jamie .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2024, 67 (01) :88-97
[49]   Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research [J].
Van Liew, Julia R. ;
Christensen, Alan J. ;
de Moor, Janet S. .
JOURNAL OF CANCER SURVIVORSHIP, 2014, 8 (03) :521-531
[50]   Perspectives of Postmenopausal Breast Cancer Survivors on Adjuvant Endocrine Therapy-Related Symptoms [J].
van Londen, G. J. ;
Donovan, Heidi S. ;
Beckjord, Ellen B. ;
Cardy, Alexandra L. ;
Bovbjerg, Dana H. ;
Davidson, Nancy E. ;
Morse, Jennifer Q. ;
Switzer, Galen E. ;
Verdonck-de Leeuw, Irma M. ;
Dew, Mary Amanda .
ONCOLOGY NURSING FORUM, 2014, 41 (06) :660-668